Parameters | Point estimates (range for sensitivity analysis) | References |
---|---|---|
Annual transition probabilities | ||
 Clinically normal MCI | 0.0341 | KLOSCADa |
 MCI clinically normal | 0.0641 | KLOSCAD |
 AN MCI mild AD | 0.0211 | KLOSCAD |
 MCI non-AD dementia | 0.0017 | KLOSCAD |
 Mild AD moderate AD | 0.3220 | [29] |
 Mild AD severe AD | 0.0420 | [29] |
 Moderate AD mild AD | 0.0430 | [29] |
 Moderate AD severe AD | 0.3390 | [29] |
Excess mortality riskb | ||
 Moderate AD | 2.57 | [29] |
 Severe AD | 7.82 | [29] |
Prevalence of amyloid positivity in MCI | 0.3910 (0.3617, 0.5556)c | Authord |
Relative risk of AD conversion of AP MCI | 7.95 (3.53, 15.20)c | SR |
Diagnostic accuracy of amyloid-PET | ||
 Sensitivity | 0.92 | [35] |
 Specificity | 1 | [35] |
Quality of life weight | ||
 Clinically normal (age ≥ 65) | 0.874 | KNHANES |
 MCI | 0.80 | [36] |
 Mild AD | 0.43 | [36] |
 Moderate AD | 0.21 | [36] |
 Severe AD | 0.17 | [36] |
Medical cost per year ($)e | ||
 Clinically normal | 0 | – |
 MCI | 794 | [36] |
 Mild AD | 2113 | [36] |
 Moderate AD | 1478 | [36] |
 Severe AD | 1819 | [36] |
Non-medical cost per year ($) | ||
 Clinically normal | 0 | – |
 MCI | 2539 | [36] |
 Mild AD | 10,956 | [36] |
 Moderate AD | 11,796 | [36] |
 Severe AD | 14,273 | [36] |
Amyloid PET cost ($) | 1041 (520, 1561)f | Author |
Additional follow-up cost per 1 visit ($) | 27 (14, 41)f | HIRA + [36] |
Treatment effect | 0.85 (0.70, 0.93)g | SR |
Virtual intervention effect for AP MCIh | 1 (0.95, 1) | Assumption |
Start age | 60 (60, 80) | – |
Discount rate | 0.05 | – |